MSD’s Keytruda backed for bladder cancer

European regulators have backed expanding approval of MSD’s immunotherapy Keytruda to include the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. Clearance of the drug is recommended for adult patients with the condition who have received prior platinum-containing chemotherapy, as well as those not eligible for cisplatin-containing chemotherapy. “There is significant need for new options that address the treatment gaps for patients in Europe with locally advanced or metastatic urothelial carcinoma, especially for those who have failed on prior platinum treatment or are ineligible for cisplatin-containing chemotherapy,” noted Dr Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories.